30 closest matches · ranked by relevance
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Neuroendocrine Tumors
Primary: Sensitivity to Correctly Diagnose NET — 75; 75; 100; 75 percent of NET correctly diagnosed
Neuroendocrine Tumors · Von Hippel-Lindau Syndrome · Hippel-Lindau Disease
Primary: Number of Lesions Detected Using the 68Gallium-DOTATATE Positron Emission Tomography (PET/Computed Tomography (CT)) Scan — 847 Number of lesions
Advanced/Metastatic Neuroendocrine Tumors
Primary: Clinical Benefit Rate — 11 Participants
Neuroendocrine Carcinoma of the Lung and Thymus
Primary: Percentage of Participants Progression-free at 9 Months Based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 0; 0; 0; 2.4 percentage of participants
Neuroendocrine Tumors · Advanced Cancer
Primary: Efficacy of Axitinib in Terms of PFS (Investigator Assessment) — 17.2; 13.1 months — p=0.324
Neuroendocrine Carcinoma
Primary: Number of Patients That Experienced a Change in Care Plans After 68GA-DOTATATE PET Scan — 19; 9; 50 participants
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Neuroendocrine Tumors
Primary: To Determine the Biodistribution of [18F] Following Single I.V Administration of [18F]-FET-βAG-TOCA Injection in Patients With a Histological Diagnosis of NET. — 0.002…
Gastroenteropancreatic Neuroendocrine Tumor
Primary: Prevalence of Malnutrition in GEP NET — 247; 152 Participants
Neuroendocrine Tumors
Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan — 54; 6; 54 Participants
Advanced NET of GI Origin · Advanced NET of Lung Origin · Neuroendocrine Tumors
Primary: Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment — 90.1; 74.6; 81.2; 49.1 Percent event-free…
Endocrine Tumors
Primary: Progression-Free Survival (PFS) — NA; 72 Weeks — p=<0.001
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Number of Participants Reported With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Drug Reactions (ADRs) — 6; 0; 5 Participants
Neuroendocrine Tumors
Primary: Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline — 1; 11; 6 Participants
Non Functioning Entero-pancreatic Endocrine Tumour
Primary: Adverse Events — 40; 46; 86 participants with any TEAEs
Neuroendocrine Tumors · Neuroendocrine Neoplasm · Gastroenteropancreatic Neuroendocrine Tumor
Primary: Overall Survival Rate at 12 Months — 54.1 % of participants
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 0.045 proportion of participants
Neuroendocrine Neoplasms
Primary: Number of [68Ga]Ga-DOTA-TATE Positive Participants (TP Participants) Among CIM Positive Participants (TP or FN Participants) — 40; 6 Participants
Neuroendocrine Tumours
Primary: Disease Control Rate (DCR) Assessed Locally at Month 9 — 35.0; 45.2; 45.0 percentage of participants — p=0.2968
Carcinoid Tumors
Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants
Adult Medulloblastoma · Childhood Medulloblastoma · Neuroblastoma
Primary: Comparison of Conventional Imaging and Gallium Ga 68-edotreotide PET Using Concordance in Tumor Detection With Pathology — 28; 0; 1; 5 Participants
Carcinoma, Large Cell · Neuroendocrine Tumors
Primary: Percentage of Participants Progression-free — 49.0 Percentage of participants
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
NeuroEndocrine Tumours
Primary: Assessment of Clinical Symptomatic Response — 77.8; 95.5; 87.5; 22.2 Percentage of Subjects — p==0.126
Large-Cell Neuroendocrine Carcinoma
Primary: Sequencing Rate (Feasibility)